Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dolasetron
Drug ID BADD_D00702
Description Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Indications and Usage For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
Marketing Status approved; investigational
ATC Code A04AA04
DrugBank ID DB00757
KEGG ID D07867
MeSH ID C060344
PubChem ID 60654
TTD Drug ID D00YLW
NDC Product Code Not Available
UNII 82WI2L7Q6E
Synonyms dolasetron | 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)- | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate | indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | dolasetron mesylate | dolasetron mesylate monohydrate | 1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate | dolasetron mesilate monohydrate | 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1) | Anzemet | MDL 73,147EF | MDL-73147EF | MDL 73147EF
Chemical Information
Molecular Formula C19H20N2O3
CAS Registry Number 115956-12-2
SMILES C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.001--
Dehydration14.05.05.001--
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Electrocardiogram abnormal13.14.05.001---
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Extrasystoles02.03.02.003---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Flatulence07.01.04.002--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal pain07.01.05.005--
Gravitational oedema02.05.04.014; 08.01.07.005---
Haematoma24.07.01.001--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001---
Hiccups07.01.06.009; 22.12.01.001--
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.010---
Hyperhidrosis08.01.03.028; 23.02.03.004--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages